
    
      Primary objectives :

      1. Response rate of primary tumor based on RECIST criteria

      Secondary objectives :

        1. Resectability based on R0 resection rate (negative margin)

        2. Toxicities of therapy with neoadjuvant Sunitinib in renal cell carcinoma

        3. Quality of life assessed by EORTC QLQ-C30 questionnaire Korean version

        4. To assess the efficacy of neoadjuvant therapy of Sunitinib by evaluating time to
           progression

        5. Overall survival rate after Sunitinib therapy

        6. Pathologic evaluation after Sunitinib therapy: the change of necrosis and microvessel
           density
    
  